论文部分内容阅读
目的 :比较培菲康和乳果糖预防肝硬化上消化道出血后肝性脑病的疗效。方法 :将2013年1月-2014年1月收入本院100例确诊肝硬化合并上消化道出血的患者随机分为培菲康组和乳果糖组(各50例),在常规治疗的基础上,分别加用培菲康及乳果糖,2周后观察疗效。结果 :治疗后比较,两组肝性脑病发生率无显著性差异(P>0.05)。培菲康组血氨含量及数字连接实验(NCT)均优于乳果糖组(P<0.05)。结论 :培菲康的治疗效果优于乳果糖,且不良反应少。
OBJECTIVE: To compare the efficacy of Pefikan and lactulose in the prevention of hepatic encephalopathy following upper gastrointestinal hemorrhage. Methods: One hundred patients diagnosed cirrhosis with upper gastrointestinal bleeding in our hospital from January 2013 to January 2014 were randomly divided into Peifeikang group and lactulose group (50 cases each). On the basis of routine treatment , Respectively, with Peifu Kang lactulose and lactose, 2 weeks after the observation effect. Results: After treatment, there was no significant difference in the incidence of hepatic encephalopathy between the two groups (P> 0.05). Pefikan group blood ammonia content and digital connection test (NCT) were better than lactulose group (P <0.05). Conclusion: Pefikang treatment is better than lactulose, and less adverse reactions.